Pharmaceutical R&D saw sustained growth in clinical trial activity and a record number of novel active substances launched in 2021, according to a new report from IQVIA.

Patient adherence is the focus of a new project launched by the Innovative Medicines Initiative (IMI) and led by Pfizer.

Queen’s University Belfast has entered into a collaboration and licensing agreement with Ipsen to research, develop, manufacture and commercialise FLIP inhibitors.